Repare Therapeutics (NASDAQ:RPTX) Shares Down 1.3% – What’s Next?

Repare Therapeutics Inc. (NASDAQ:RPTX)’s stock price dropped 1.3% on Friday . The company traded as low as $1.45 and last traded at $1.47. Approximately 129,515 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 253,318 shares. The stock had previously closed at $1.49.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price target on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 7th.

Repare Therapeutics Stock Performance

The stock has a market cap of $63.05 million, a PE ratio of -0.74 and a beta of 0.85. The company’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.46.

Institutional Investors Weigh In On Repare Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its position in shares of Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock valued at $45,000 after purchasing an additional 23,127 shares during the last quarter. Vontobel Holding Ltd. grew its stake in shares of Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock valued at $46,000 after acquiring an additional 11,000 shares during the period. Lynx1 Capital Management LP bought a new position in shares of Repare Therapeutics during the 4th quarter valued at approximately $104,000. JPMorgan Chase & Co. grew its stake in shares of Repare Therapeutics by 2,144,950.0% during the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock valued at $112,000 after acquiring an additional 85,798 shares during the period. Finally, Stifel Financial Corp grew its stake in shares of Repare Therapeutics by 73.1% during the 4th quarter. Stifel Financial Corp now owns 89,500 shares of the company’s stock valued at $117,000 after acquiring an additional 37,800 shares during the period. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.